# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Virios Therapeutics (NASDAQ:VIRI) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of...
- New patent would extend coverage and expand potential value of Virios' antiviral pipeline globally –- Active Long-COVID c...
Virios Therapeutics (NASDAQ:VIRI) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $...
Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing...